In a double-blind study, we compared the final outcome of 99 Bell's palsy patients treated with either acyclovir-prednisone (53 patients) or placebo-prednisone (46 patients). For patients receiving acyclovir, the dosage was 2,000 mg (400 mg 5 times daily) for 10 days. Electrical tests included electroneurography and the maximal stimulation test. Univariate comparisons of outcome and electrical tests between the two groups were made with χ2 analysis, Fisher's exact test, and t-tests. The outcome in acyclovir-prednisone-treated patients was superior to that in placebo-prednisone-treated patients. Treatment with acyclovir-prednisone was statistically more effective in returning volitional muscle motion (recovery profile of 10; p = .02) and in preventing partial nerve degeneration (p = .05) than placebo-prednisone treatment. The t-tests indicated that the recovery profile and index means were significantly better for the acyclovir-treated group (recovery profile t = 1.99, p = .051; recovery index t = 2.10, p = .040). We conclude that acyclovir-prednisone is superior to prednisone alone in treating Bell's palsy patients and suggest that herpes simplex is the probable cause of Bell's palsy.
NakamuraKYanagiharaN. Neutralization antibody to herpes simplex virus type 1 in Bell's palsy. Ann Otol Rhinol LaryngolSuppl1988; 97(suppl 137): 18–21.
7.
JonssonL. On the etiology of Bell's palsy: immunological and magnetic resonance imaging abnormalities [Dissertation]. Uppsala, Sweden: Uppsala University, 1987.
8.
JonssonLAlmGThomanderL. Elevated serum interferon levels in patients with Bell's palsy. Otolaryngol Head Neck Surg1989; 115: 37–40.
9.
TienRDillonWPJacklerRK. Contrast-enhanced MR imaging of the facial nerve in 11 patients with Bell's palsy. AJNR Am J Neuroradiol1990; 11: 735–41.
10.
ProctorBCorgillDAProudG. The pathology of Bell's palsy. Trans Am Acad Ophthalmol Otolaryngol1976; 82: 70–80.
11.
ListenSLKleidMS. Histopathology of Bell's palsy. Laryngoscope1989; 99: 23–6.
12.
AdourKKWingerdJBellDMManningJJHurleyJP. Prednisone treatment for idiopathic facial paralysis (Bell's palsy). N Engl J Med1972; 287: 1268–72.
13.
KriegerN. Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. Am J Public Health1992; 82: 703–10.
14.
RuboyianesJMAdourKKSantosDQVon DoerstenPG. The maximal stimulation and facial nerve conduction latency tests: Predicting the outcome of Bell's palsy. Laryngoscope1994; 104(suppl 61).
SinhaPKKeithRWPensakML. Predictability of recovery from Bell's palsy using evoked electromyography. Am J Otol1994; 15: 769–71.
17.
LewisBIAdourKK. An analysis of the Adour-Swanson and House-Brackmann grading systems for facial nerve recovery. Eur Arch Otorhinolaryngol1995; 252: 265–9.
18.
PearsonBW. Editorial. Otolaryngol Head Neck Surg1985; 93: 145.
19.
SatterthwaiteFE. An approximation distribution of estimates of variance components. Biometrics Bull1946; 2: 110–4.
20.
SugitaTMurakamiSYanagiharaNFujiwaraYHirataYKurataT. Facial nerve paralysis induced by herpes simplex virus in mice: An animal model of acute and transient facial paralysis. Ann Otol Rhinol Laryngol1995; 104: 574–81.
21.
AvielAOstfeldEBursteinRMarshakGBentwichZ. Peripheral blood T and B lymphocyte subpopulations in Bell's palsy. Ann Otol Rhinol Laryngol1983; 92: 187–91.
22.
BummPMiillerECGrimm-MüllerUSchlimokG. T-Lymphozytensubpopulationen und HLA-DR-Antigene beim Horsturz, der Neuropathia vestibularis, dem Morbus Ménière und der Bellschen Parese [T-lymphocyte subpopulations and HLA-DR antigens in hearing loss of vestibular neuropathy, Ménière's disease and Bell's palsy]. Laryngorhinootologie1991; 70: 260–6.
23.
BummPSchlimokG. The results of immunological regulation and immunogenetics in Bell's palsy. In: CastroD, ed. Proceedings of the Sixth International Symposium on the Facial Nerve, Rio de Janeiro, Brazil, October 2–5, 1988. Amsterdam, the Netherlands: Kugler & Ghedini, 1989: 1–3.
24.
AbramskyOWebbCTeitelbaumDAnionR. Cellular immune response to peripheral nerve basic protein in idiopathic facial paralysis (Bell's palsy). J Neurol Sci1975; 26: 13–20.
25.
EdstromSHannerPAndersenORosenhallUVahlneAKarlssonB. Elevated levels of myelin basic protein in CSF in relation to auditory brainstem responses in Bell's palsy. Acta Otolaryngol (Stockh)1987; 103: 198–203.
26.
DjupeslandGBerdalPJohannessenTADegréMStienRSkredeS. The role of viral infection in acute peripheral facial palsy. Acta Otolaryngol (Stockh)1975; 79: 221–7.
27.
TavernerDCohenSBHutchinsonBC. Comparison of corticotrophin and prednisolone in treatment of idiopathic facial paralysis (Bell's palsy). Br Med J1971; 4: 20–2.
28.
AustinJRPeskindSPAustinSGRiceOH. Idiopathic facial nerve paralysis: A randomized double blind controlled study of placebo versus prednisone. Laryngoscope1993; 103: 1326–33.
29.
Aetiology of Bell's palsy [Editorial]. Br Med J1971; 4: 2–3.
30.
AdourKK. The bell tolls for decompression [Editorial]. N Engl J Med1975; 292: 748–9.
31.
AdourKKBylFMHilsingerRLJrKahnZMSheldonMI. The true nature of Bell's palsy: Analysis of 1,000 consecutive patients. Laryngoscope1978; 88: 787–801.
32.
AdourKKWingerdJ. Idiopathic facial paralysis (Bell's palsy): Factors affecting severity and outcome in 446 patients. Neurology1974; 24: 1112–6.
33.
KerbavazRJHilsingerRLJrAdourKK. The facial paralysis prognostic index. Otolaryngol Head Neck Surg1983; 91: 284–9.
34.
WolfSMWagnerJHJrDavidsonSForsytheA. Treatment of Bell palsy with prednisone: A prospective, randomized study. Neurology1976; 28: 158–61.
35.
DjupeslandGDegreMStienRSkredeS. Acute peripheral facial palsy: Part of a cranial polyneuropathy?Arch Otolaryngol1977; 103: 641–4.
